We are pleased to introduce our new BD Tau workflow together with IBL/ Tecan. This is the start of a close collaboration to extend the toolbox of biomarkers for clinical and academic research in the field of Alzheimer’s disease.
Brain-derived Tau – easy measurable in blood
Neurodegenerative diseases like Alzheimer's leave molecular traces, including in the form of tau protein. However, only a small portion of this actually originates in the brain. Conventional total tau measurement in the blood therefore often provides inaccurate signals. (https://www.nature.com/articles/s41467-024-47286-5)
Our BD-Tau workflow makes the difference.
Through targeted immunoprecipitation and the specific detection of the brain-derived tau isoform, our workflow enables, for the first time, a sensitive and specific measurement of brain-derived tau in blood-based samples, with standard laboratory equipment.
Your advantages at a glance:
Targeted: Specific detection of the brain-derived tau fraction
Easily accessible: Can be performed using standard laboratory equipment
Powerful: Combination of target enrichment through IP and Luminescence-based ELISA for high sensitivity
Suitable for research: Ideal for academic research and studies on Alzheimer's disease and neurodegenerative processes
Minimally invasive: Blood instead of CSF – for longitudinal biomarker assessment
For more information, please visit our homepage:
https://www.roboscreen.com/products/neurodegeneration/